Stock Analysis
Baxter International Inc.BAX
Sector: Healthcare · Industry: Surgical & Medical Instruments & Apparatus
AnalystsHold20 analystsPrice is 76% of the way from the year's low to its high.
Cash covers 22% of debt · Q2 2026.
PMP Verdict
Cheap for a reason — weak fundamentals
Strengths
- Quality65
Risks
- Growth0
- Profitability17
Cheap for a reason — fundamentals remain weak.
What's happening with BAX
Profile
growth, profitability and financial health lag behind.
How is each axis scored?
- Valuation67/100 · Moderate
- P/E vs own history (n/a)10/25
- FCF yield (7.1%)20/25
- P/S (1.1x)25/25
- EV/EBIT (22.1x)12/25
- Growth0/100 · Weak
- Revenue CAGR (-3.2%)0/25
- Net income CAGR (n/a)0/25
- EPS CAGR 5Y (n/a)0/25
- Fwd implied growth (n/a)0/25
- Profitability17/100 · Weak
- ROIC (5.4%)5/25
- ROE (-17.2%)0/25
- Net margin (-9.3%)0/25
- Operating margin (8.1%)12/25
- Financial Health41/100 · Weak
- Altman Z (2.14)18/25
- Current ratio (1.95)18/25
- Interest coverage (-1.0x)0/25
- Net cash / debt (D/A 38%)5/25
- Quality65/100 · Moderate
- Piotroski F (5/9)15/25
- Beneish M (-2.61)25/25
- FCF conversion (-88%)0/25
- Margin stability (σ 3.7%)25/25
- Moat51/100 · Moderate
- ROIC >12% years (6/10 yrs)13/25
- Median gross margin (39.6%)13/25
- FCF-positive years (10/10 yrs)25/25
- Worst-year net margin (worst -16.1%)0/25
Risk Flags
- ⚠3 loss-making years in recent history
- ⚠Interest coverage -1.0× — thin debt cushion
- ⚠Revenue shrinking 3.2%/yr
About Baxter International Inc.
Baxter offers a variety of medical supplies and equipment to providers. Show more
From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.
Headquarters: DEERFIELD, IL · Employees: 37,500 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
67BP/E (TTM)—
Price / TTM EPS (own statements)
P/FCF16.3xB
Grade B: FairPrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield7.1%A
Grade A: ValueTTM (OCF − CapEx) / Market Cap — vs own 5Y history: 1.2%–8.6% · 96th pct
P/S (TTM)1.14xA
Grade A: CheapPrice / TTM Revenue (own statements) — vs own 5Y history: 0.7x–3.6x · 20th pct
EV/EBIT22.1xC
Grade C: ExpensiveEnterprise value / TTM EBIT (D&A not in our data) — capital-structure neutral — vs own 5Y history: 7.9x–114.6x · 30th pct
EV/Sales1.8xA
Grade A: CheapEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E11.6xA
Grade A: CheapPrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio2.12xA
Grade A: FairPrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio-0.02A
Grade A: CheapFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield1.38%A
Grade A: PaysTTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio4.0%A
Grade A: SafeDividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
17EROIC5.4%D
Grade D: LowNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE-17.2%D
Grade D: WeakReturn on Equity. Neg. equity = heavy buybacks
ROA-5.3%D
Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin-9.3%D
Grade D: LowNet Income / Revenue
Operating Margin8.1%D
Grade D: LowTTM EBIT / TTM Revenue
Gross Margin30.1%C
Grade C: AverageGross Profit / Revenue
FCF Margin8.1%C
Grade C: AverageFCF / Revenue
True FCF Margin7.1%C
Grade C: AverageTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
0ERevenue CAGR-3.2%D
Grade D: LowCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR—
Compound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)—
Compound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth—
Analyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)+1.4%B
Grade B: FlatShare count change over 5Y
SBC / Net Income—
Stock-based comp/Net income. >30% = dilution risk
SBC / Revenue1.0%A
Grade A: LowTTM stock-based comp / TTM Revenue
Financial Health
41D+Altman Z-Score2.14C
Grade C: Gray zoneBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio1.95xC
Grade C: OkCurrent Assets/Liabilities
Quick Ratio1.15xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage-1.0xD
Grade D: RiskyEBIT/Interest. >10 Strong
Debt Repayment8.1yC
Grade C: AverageYears to repay net debt via FCF
Net Debt/EBIT8.1xD
Grade D: HighLeverage. <2x Low, >4x High
Debt/Equity1.56xC
Grade C: MedDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt0.22xD
Grade D: ThinCash covers how much of total debt. >1 = could repay all debt from cash
Quality
65BPiotroski F-Score5/9C
Grade C: AverageFinancial strength 0–9. >7 Strong
Beneish M-Score-2.61A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion-87.6%D
Grade D: PoorFCF / Net Income
Margin Stability3.7%A
Grade A: StableEBIT margin std deviation. Lower = stable
Capex / Revenue3.4%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.57xC
Grade C: AverageRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Hider Andrew P. Filed | Hider Andrew P. | Tax withholding | -54276 | |
Foster Julie Filed | Foster Julie | Tax withholding | -2098 | |
Teaff James Filed | Teaff James | Tax withholding | -750 | |
Wallace Steven P. Filed | Wallace Steven P. | Tax withholding | -153 | |
Teaff James Filed | Teaff James | Tax withholding | -321 |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Zielinski Anita A Filed | Zielinski Anita A | Grant / award | +13.4K | |
Wilkes David S. Filed | Wilkes David S. | Grant / award | +12.8K | |
Wendell Amy McBride Filed | Wendell Amy McBride | Grant / award | +12.8K |
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
51CROIC >12% Years6/10 yrsC
Grade C: ModerateShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)39.6%C
Grade C: ModerateMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years10/10 yrsA
Grade A: DurableShare of completed fiscal years with positive free cash flow
Net Margin Floor-16.1%D
Grade D: WeakWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)—
TTM net income per share (Finnhub fallback)
Cash / Share$4.16
Cash & short-term investments per share (Finnhub)
Book Value / Share$12.00
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$9.67B
Total debt obligations (short + long term)
Cash & Equiv.$2.15B
Cash and short-term investments
Net Debt$7.52B
Total Debt minus Cash. Negative = Net Cash position
Total Equity$6.18B
Shareholders' equity (book value)
Asset / Liability1.45xC
Grade C: AdequateTotal Assets / Total Liabilities
Market
Market Cap$13.08B
Current Market Capitalization
Beta0.67B
Grade B: DefensivePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: Baxter International Inc. (BAX)
BAX is down 1.86% at the last close. Piotroski F-Score of 5/9 indicates mixed fundamentals for Baxter International Inc.. Altman Z-Score of 2.14 falls in the grey zone (1.81–2.99) — financial distress is unlikely but not ruled out. Beneish M-Score of -2.61 suggests a low likelihood of earnings manipulation.
- Revenue has been contracting (CAGR ≈ -3%), which weighs on the growth outlook.
- Takes ~8.1 years to repay net debt from free cash flow.
- Interest coverage of -1.0× leaves little room for earnings shocks.
- Baxter International Inc. posted a net loss in 3 of 10 available completed fiscal years (2016–2025).
See how BAX ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all BAX moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 15 | Regular | 25.76 | +3.87% | 2.43 |
| Oct 15 | After-hours | 25.65 | +3.41% | 2.11 |
| Oct 5 | Regular | 24.22 | +3.09% | 2.35 |
| Oct 5 | After-hours | 24.22 | +3.11% | 2.37 |
| Sep 22 | Regular | 23.67 | +3.23% | 3.13 |
Frequently Asked Questions about BAX
What is the current Baxter International Inc. (BAX) stock price?
BAX is trading at $25.28 at the last market close, down 1.86% on the session. PreMarketPrice tracks BAX pre-market, intraday and after-hours prices.
Is BAX stock a buy right now?
PreMarketPrice's quantitative model rates Baxter International Inc.'s financial health at 41/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is BAX stock overvalued?
Baxter International Inc. trades at a trailing P/E of n/a and our valuation score rates it 67/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Baxter International Inc. report earnings?
No confirmed earnings date is currently scheduled for BAX. The Earnings section lists recent reports and updates as dates are announced.
What sector does Baxter International Inc. operate in?
Baxter International Inc. operates in the Healthcare sector, within the Surgical & Medical Instruments & Apparatus industry. The Related Stocks section lists sector peers for comparison.
What does Baxter International Inc. do?
Baxter offers a variety of medical supplies and equipment to providers.
About Baxter International Inc. (BAX) Stock
Baxter International Inc. (BAX) is a US-listed stock operating in the Healthcare sector, specifically the Surgical & Medical Instruments & Apparatus industry. As of the latest update, Baxter International Inc. is trading at $25.28, down 1.86% on the day with a market capitalization of $13.1 billion. The financial health score for BAX is 41/100, which indicates weak financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for BAX stock.
BAX Stock Analysis & Key Metrics
On PreMarketPrice, you can track Baxter International Inc. (BAX) across multiple dimensions:
- Pre-market price & movement: Real-time BAX stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for BAX with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Baxter International Inc. across multiple reporting periods.
- Financial health score: A composite score of 41/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for BAX.
- Sector peers: Compare BAX against 6 other healthcare stocks on key financial metrics.
Is BAX a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Baxter International Inc. (BAX) as an investment. The financial health score of 41/100 suggests weak financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Baxter International Inc. (BAX) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.